Preclinical dosimetric evaluation of Ixolaris labeled with 99mTc and Translacional Model
DOI:
https://doi.org/10.15392/bjrs.v7i3.853Palavras-chave:
preclinical dosimetric, 99mTc- Ixolaris, SPECT, imaging dosimetry methodResumo
ABSTRACT
This study aimed to determine the biokinetic model for Ixolaris labelled with 99mTc radiotracer in mice by means of an imaging dosimetry method to estimate the absorbed and effective doses resulting from the diagnosis of melanoma and metastases in humans. C57BL6 mice induced animals with cell line B16-F10 murine melanoma were tested. It was determined by Single Photon Emission Tomography Computed (SPECT) images a latency period of 15 to 21 days for the development of lung metastasis in mice. The 99mTc-Ixolaris radiopharmaceutical was intravenously administered in a caudal vein, and SPECT images were acquired approximately at 0.5 h, 1.5 h, 2.5 h, 3.5 h and 24 h post-administration for analysis and biodistribution quantification. The biokinetic model was determined and cumulative activity to estimate the absorbed dose in each organ was calculated. The mass and metabolic differences between mice and humans were considered and used to extrapolate the data for different scales. Absorbed doses in irradiated target organs were calculated for the source organs based on dose factors provided by the software MIRDOSE and Olinda/EXM (S factor). Afterwards, the effective doses were estimated. The metabolic differences were 7,02 in this study. The dosimetric results indicated an estimated effective dose of 4.3 mSv for diagnostic exams conducted in human melanoma patients for an administered activity of 25.7 MBq. Comparing with effective doses resulting from other 99mTc diagnostic techniques, effective dose ranging from 0.6 to 4.8 mSv it was concluded that the procedure should proceed into a Clinical Phase in humans.
Downloads
Referências
Martic-Kehl, R. Mschibli, A.P. Schubiger. Can animal data predict human outcome? Problems and pitfalls of translational animal research. Eur J Nucl Med Mol Imaging. 2012; 39:1492-1496.
International Atomic Energy Agency – IAEA. Human Health Reports No. 9 Quantitative Nuclear Medicine Imaging: Concepts, Requirements and Methods. Vienne, 2014.
G. Sgouros et al. Three-dimensional imaging- based radiobiological dosimetry. Semin Nucl Med. 2008. 38(5):321-334.
M.G Stabin. Fundamentals of Nuclear Medicine Dosimetry. 1st ed. Nashville, TN, USA: Springer;2008.
Barboza, T., Gomes, T., Mizurini, D., et. al. 99mTc-ixolaris targets glioblastoma-associated tissue factor: In vitro and pre-clinical applications. Thromb Res 2015,15:S0049.
McParland, B.J. Nuclear Medicine Radiation Dosimetry - Advanced Theoretical Principles. 1st ed. Springer;2010.
S, Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet #11 (Society of Nuclear Medicine 1975).
Elvas, Vangestel, C., Rapic, S. Characterization of 99mTc- Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis. Mol Imaging Biol 2015.
International Comission on Radiological Protection – ICRP. Recommendations of the International Commission on Radiological Protection. ICRP Publication 103 (2007).
International Comission on Radiological Protection – ICRP. Basic Anatomical and Physiological Data for Use in Radiological Protection Reference Values. ICRP Publication 89 (2002).
International Atomic Energy Agency – IAEA. Basic Safety Standards for Protection against Ionizing Radiation and for Safety of Radiation Sources. Vienne, 1996.
Downloads
Publicado
Edição
Seção
Licença
Direitos autorais (c) 2019 Brazilian Journal of Radiation Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade. Declaro, ainda, que uma vez publicado na revista Brazilian Journal of Radiation Sciences, editada pela Sociedade Brasileira de Proteção Radiológica, o mesmo jamais será submetido por mim ou por qualquer um dos demais co-autores a qualquer outro periódico. Através deste instrumento, em meu nome e em nome dos demais co-autores, porventura existentes, cedo os direitos autorais do referido artigo à Sociedade Brasileira de Proteção Radiológica, que está autorizada a publicá-lo em meio impresso, digital, ou outro existente, sem retribuição financeira para os autores.
Licença
Os artigos do BJRS são licenciados sob uma Creative Commons Atribuição 4.0 Licença Internacional, que permite o uso, compartilhamento, adaptação, distribuição e reprodução em qualquer meio ou formato, desde que você dê o devido crédito ao (s) autor (es) original (is) e à fonte, forneça um link para a licença Creative Commons, e indique se mudanças foram feitas. As imagens ou outro material de terceiros neste artigo estão incluídos na licença Creative Commons do artigo, a menos que indicado de outra forma em uma linha de crédito para o material. Se o material não estiver incluído no licença Creative Commons do artigo e seu uso pretendido não é permitido por regulamentação legal ou excede o uso permitido, você precisará obter permissão diretamente do detentor dos direitos autorais. Para visualizar uma cópia desta licença, visite http://creativecommons.org/licenses/by/4.0/
